[HTML][HTML] Effectiveness and Safety of Pembrolizumab in Recurrent and Relapsed Classic Hodgkin Lymphoma: A Systematic Review
MF Hossain, M Kharel, M Akter, B Parajuli, I Yadav… - Cureus, 2023 - ncbi.nlm.nih.gov
Classical Hodgkin lymphoma (cHL) has achieved high cure rates as a result of recent
advancements in treatment. However, recurring or relapsed illness still poses a therapeutic …
advancements in treatment. However, recurring or relapsed illness still poses a therapeutic …